N@N

Finkelstein Thompson LLP Announces Investigation of CPEX Pharmaceuticals, Inc.

^{Published on 2011-01-04 18:00:44 - Market Wire}
 

WASHINGTON--([ BUSINESS WIRE ])--Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of CPEX Pharmaceuticals, Inc. (aCPEXa or the aCompanya) (NASDAQ:CPEX) concerning the sale of the Company to FCB I Holdings Inc., a subsidiary of Footstar Inc. (aFootstara) for $27.25 in cash per share, in a transaction valued at approximately $76.6 million.

The investigation is focused on the potential unfairness of the deal price to CPEX shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interests among CPEX Board members. Notably, CPEX shares have traded as high as $29.47 as recently as June 15, 2010.

If you are interested in discussing your rights as a CPEX shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at [ contact@finkelsteinthompson.com ].

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our web site at [ www.finkelsteinthompson.com ]. Attorney advertising. Prior results do not guarantee similar outcomes.